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	 A	 simple,	 rapid	 and	 sensitive	 LC‐MS/MS	 method	 was	 developed	 and	 validated	 for	 the
quantification	 of	 azithromycin	 (AZI)	 in	 human	 plasma.	 Sildenafil	 citrate	 was	 used	 as	 an
internal	standard.	The	analytes	were	extracted	 from	human	plasma	samples	by	liquid‐liquid
extraction	technique.	The	reconstituted	samples	were	chromatographed	on	a	reversed	‐	phase
column	C18,	50	×	2.1	mm,	5	µm	from	Waters,	by	using	a	80:20	(v:v)	mixture	of	acetonitrile	and
0.1%	formic	acid	in	water	as	the	mobile	phase	at	a	 flow	rate	of	0.5	mL/min.	The	calibration
curve	was	linear	(r2	>	0.99)	over	the	concentration	range	of	5.0‐1500.0	ng/mL.	The	results	of
the	 intra‐	 and	 inter‐day	precision	 and	accuracy	studies	were	within	 the	acceptable	 limits.	A
run	 time	 of	 0.5	 min	 for	 each	 sample	 made	 it	 possible	 to	 analyze	 more	 than	 400	 plasma
samples	per	day.	
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1.	Introduction	
	
Azithromycin	designated	chemically	as	2R,3S,4R,5R,8R,10R,	
11R,12S,13S,14R)‐2‐ethyl‐3,4,10‐trihydroxy	 3,5,6,8,10,12,14‐
heptamethyl‐15‐oxo‐11‐{[3,4,6‐trideoxy‐3‐(dimethylamino)‐β‐
D‐xylo‐]oxy}‐1‐oxa‐6‐azacyclopentadec‐13‐yl2,6‐dideoxy‐3‐C	
methyl‐3‐O‐methyl‐α‐L‐ribo‐hexopyranoside	[1]	(Figure	1)	is	a	
semi‐synthetic	 macrolide	 antibiotic	 of	 the	 azalide	 class.	
Azithromycin	inhibits	bacterial	protein	synthesis	by	binding	to	
the	 50S	 ribosomal	 subunit	 of	 the	 bacterial	 70S	 ribosome.	 It	
inhibits	peptidyl	transferase	activity	and	interferes	with	amino	
acid	 translocation	 during	 the	 process	 of	 translation.	 Its	 effect	
may	 be	 bacteriostatic	 or	 bactericidal	 depending	 on	 the	
organism	 and	 the	 drug	 concentration.	 Its	 long	 half‐life,	which	
enables	 once	 daily	 dosing	 and	 shorter	 administration	
durations,	 is	 a	 property	 distinct	 from	 other	 macrolides.	 It	 is	
derived	from	erythromycin;	however,	it	differs	chemically	from	
erythromycin	 in	 that	 a	 methyl‐substituted	 nitrogen	 atom	 is	
incorporated	into	the	lactone	ring	as	shown	in	Figure	1.		
Like	erythromycin,	it	appears	to	bind	to	the	same	receptor,	
50S	ribosomal	subunits	of	susceptible	bacteria	and	suppresses	
protein	synthesis.	It	is	used	primarily	to	treat	various	bacterial	
infections,	 such	 as	 aerobic	 gram‐positive	microorganisms	 and	
aerobic	 gram‐negative	 microorganisms.	 The	 incorporation	 of	
the	 nitrogen	 into	 the	 ring	 significantly	 alters	 the	 chemical,	
microbiologic	 and	 pharmacokinetic	 properties	 of	 AZI.	 It	
exhibits	 a	 more	 extensive	 spectrum	 of	 activity,	 greater	 acid	
stability	and	more	favorable	pharmacokinetic	parameters	than	
erythromycin	[1].	
 
	
Figure	1.	Chemical	structure	of	azithromycin.	
	
Several	methods	have	been	developed	for	determination	of	
AZI	 in	 pharmaceutical	 dosage	 forms.	 These	 methods	 include	
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high‐performance	 liquid	 chromatography	 (HPLC)	 and	 micro‐
biological	methods.		
Chromatographic	 separation	 is	 one	 of	 the	 essential	 and	
powerful	 components	 of	 the	 most	 quantitative	 analyses	 and	
HPLC	 is	 currently	 the	 most	 versatile	 tool	 which	 satisfies	 the	
needs	for	an	optimum	separation	[2].	AZI	has	been	analyzed	by	
spectrophotometric	 methods	 [3‐5],	 high‐perfor‐mance	 liquid	
chromatography	 using	 fluorescence	 [6‐8],	 electro‐chemical	
using	amperometric	detection	[9‐10]	and	coulometric	detection	
[11‐13]	 and	 mass	 spectrometry	 detector	 [14‐17]	 for	
quantification	 in	 bulk	 material	 and	 pharmaceutical	 dosage	
forms.	 Fluorescence	 detection	 requires	 complicated	 sample	
pretreatment	 involving	 pre‐column	 derivatization	 of	 the	
analyte.	 Assay	 procedures	 making	 use	 of	 electrochemical	
detection	 is	 often	 very	 time	 consuming,	 both	 in	 the	 sample	
preparation	 steps	and	 the	 chromatography.	The	United	States	
Pharmacopoeaia	(USP)	method	[18]	describes	a	high	pH	mobile	
phase	(pH	=	11)	as	well	as	a	specific	column	(Gamma	alumina)	
which	is	quite	expensive	and	difficult	to	obtain	commercially	as	
many	of	the	column	manufacturers	do	not	supply	this	column.	
Also,	 the	 USP	method	 employs	 amperometric	 electrochemical	
detection,	 which	 is	 not	 available	 in	 many	 laboratories.	
Therefore,	 there	 is	 a	 need	 for	 a	 convenient	 and	 effective	
method	 for	 determination	 of	 AZI	 in	 pharmaceutical	 dosage	
forms.	 Liquid	 chromatography	 with	 UV	 detection	 has	 been	
already	employed	 for	 the	analysis	of	AZI	either	 in	 tablets	 [19]	
or	 in	 raw	 material	 [20]	 or	 in	 both	 [21].	 Mass	 spectrometry	
methods	 may	 have	 the	 highest	 sensitivity,	 but	 the	
determination	 process	 is	 complex	 [22].	 Various	 extraction	
methods	 have	 been	 reported	 for	 extraction	 of	 Azithromycin	
form	 plasma	 like,	 protein	 precipitation	 [23,24],	 pressurized	
liquid	 extraction	 (PLE)	 [25],	 liquid‐liquid	 extraction	 [26,27]	
and	solid	phase	extraction	[28,29].	
The	 objective	 of	 the	 study	 was	 to	 develop	 simple,	 fast,	
sensitive,	 selective,	 accurate	 and	 economic	 method	 for	
quantification	 of	 Azithromycin	 in	 human	 plasma	 following	
liquid‐liquid	 extraction	 by	 LC‐MS/MS.	 Unlike	 other	 LC‐MS	
methods,	 the	 presented	 method	 has	 the	 advantages	 of	 short	
run	 time	 (about	 0.5	 min)	 which	 made	 it	 possible	 to	 analyze	
more	 than	 400	 plasma	 samples	 per	 day	 and	 a	 wide	 range	 of	
linearity	 (5‐1500	 ng/mL).	 Sildenafil	 citrate	 (Figure	 2),	
designated	chemically	as	1‐[[3‐(6,7‐dihydro‐1‐methyl‐7‐oxo‐3‐
propyl‐1Hpyrazolo[4,3‐d]pyrimidin‐5‐yl)‐4‐ethoxyphenyl]	
sulfonyl]‐4‐methylpiperazine	 citrate	 was	 used	 as	 internal	
standard	(IS).	
	
	
	
Figure	2.	Chemical	structure	of	sildenafil	citrate	(IS).
	
	
2.	Experimental	
	
2.1.	Chemicals	and	reagents	
	
Azithromycin	 reference	 standard	 (B.N:	 1182090426;	
purity:	97.80%)	was	obtained	from	CSPC,	OUYI	Pharmaceutical	
Co.	 Ltd	 (Shijiazhuang,	 China).	 Sildenafil	 citrate	 (B.N.	
586032009SC;	 purity:	 99.20%)	 was	 employed	 as	 an	 internal	
standard	 (IS)	 obtained	 from	 BDR	 Pharmaceuticals	
International	 PVT.	 ITD	 (Mumbai,	 India).	Water	 for	 HPLC	was	
purchased	 from	Merck,	Germany.	Formic	acid	and	acetonitrile	
were	of	HPLC	grade	and	purchased	from	Sigma‐Aldrich	Chemie	
Gmbh	 (Munich,	 Germany).	 Sodium	 carbonate	 and	 tert‐butyl	
methyl	 ether	were	 supplied	 by	 (Romil	 Ltd.,	 London,	UK).	 The	
control	 human	 plasma	 sample	 was	 procured	 from	 VACSERA	
(Cairo,	Egypt).	
	
2.2.	Equipment	
	
Acquity	 Ultra‐Performance	 Liquid	 Chromatographic‐
MS/MS	(UPLC‐MS/MS)	system	equipped	with	UPLC	C18	(50	×	
2.1,	5	µm)	column,	tandem	mass	triple‐quadruple	detector	and	
electro	 spray	 ionization	 (ESI)	 probe	 was	 used	 for	 the	 assay	
(Waters,	 USA).	 The	 system	 included	 a	 vacuum	 degasser,	 a	
quaternary	pump,	a	thermostatted	auto‐sampler	and	a	column	
oven	compartment.	Data	acquisition	and	data	integration	were	
done	 using	 Empower™	 Ver.2	 Chromatography	 Data	 Software	
(CDS)	solutions.		
	
2.3.	Chromatographic	conditions	
	
Separations	were	performed	on	UPLC	C18	(50	×	2.1,	5	µm)	
column.	A	mobile	phase	consisting	of	a	mixture	of	acetonitrile‐
0.1	%formic	acid	(80:20,	v:v)	was	delivered	at	a	flow	rate	of	0.5	
mL/min	 into	 the	mass	 spectrometer.	 Aliquot	 of	 7.5	 μL	 of	 the	
processed	 samples	were	 injected	 into	 the	 column,	which	was	
kept	 at	 30	 °C.	 Quantification	 was	 achieved	 with	 MS‐MS	
detection	 in	 positive	 ion	mode	 for	 both	 the	 internal	 standard	
and	 azithromycin	 using	 Waters	 ACQUITY	 TQD	 (triple	 quad	
detector)	 MS/MS	 (Foster	 City,	 CA,	 USA).	 The	 compound	
parameters	viz.	the	collision	energy	(CE)	and	Cone	voltage	(CV)	
were	 38	 and	 40	 volt	 for	 azithromycin	 and	 30	 and	 50	 volt	 for	
sildenafil	 citrate.	 Detection	 of	 the	 ions	was	 carried	 out	 in	 the	
multiple‐reaction	monitoring	mode	(MRM),	by	monitoring	m/z	
749.62/82.87	 for	 azithromycin	 ion	 and	m/z	 475.34/99.75	 for	
sildenafil	citrate	ion	(IS).	Data	acquisition	and	data	integration	
were	done	using	Empower™	Ver.	2	CDS	software	solutions.		
	
2.4.	Preparation	of	stock	solutions,	secondary	and	working	
solutions		
	
2.4.1.	Stock	solution	of	azithromycin	for	calibration	and	
quality	control	
	
A	stock	standard	solution	of	azithromycin	(100	μg/mL)	was	
prepared	 by	 accurate	 weighing	 and	 transferring	 10	 mg	 of	
azithromycin	 into	 a	 100	 mL	 volumetric	 flask	 and	 diluting	 to	
volume	with	the	mobile	Phase.	
	
2.4.2.	Working	solutions	of	azithromycin		
	
Different	working	standard	solutions	of	azithromycin	(B,	C,	
D,	E	and	F)	were	prepared	by	 transferring	 (10	mL,	1	mL,	100	
µL,	10	µL	and	1	µL,	respectively)	of	stock	solution	each	 into	a	
100	mL	 volumetric	 flask	 and	 diluting	 to	 volume	 with	 mobile	
phase	to	give	a	final	concentrations	of	(10	μg/mL,	1	μg/mL,	100	
ng/mL,	10	ng/mL	and	1	ng/mL,	respectively).	
	
2.4.3.	Stock	solution	of	internal	standard	for	calibration	and	
quality	control	
	
A	stock	standard	solution	of	sildenafil	citrate	(100	µg/mL)	
was	prepared	by	accurately	weighing	and	transferring	10	mg	of	
sildenafil	citrate	into	a	100	mL	volumetric	flask	and	diluting	to	
volume	with	mobile	phase.	
	
2.4.4.	Working	solution	of	internal	standard	
	
A	 working	 standard	 solution	 of	 sildenafil	 citrate	 (0.5	
µg/mL)	was	prepared	by	transferring	0.5	mL	of	stock	solution	
into	 a	 100	 ml	 volumetric	 flask	 and	 diluting	 to	 volume	 with	
mobile	 phase.	 Human	 plasma	 was	 chromatographed	 prior	 to	
use	 to	 determine	 possible	 interference	 with	 azithromycin	 or	
internal	standard.		
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Table	1.	The	optimum	Multiple	Reaction	Mode	parameters	for	both	drug	and	IS.	
No	 Drug	/	IS	 Precursor	(Da)	 Product	(Da)	 Dwell	(sec)	 Cone	voltage	(V)	 Collision	energy	(V)	
1	 Sildenafil	(IS)		 475.34	 99.75 0.100 50 30	
2	 Azithromycin 749.62	 82.87 0.100 40 38	
	
	
No	 significant	 interferences	 were	 observed	 in	 the	 lots	 of	
human	 plasma	 used	 for	 the	 preparation	 of	 calibration	
standards	and	quality	control	samples.		
	
2.5.	Preparation	of	calibration	curve	and	quality	control	
solutions	
	
Standard	 curve	 was	 produced	 by	 preparing	 six	 plasma	
standards	 over	 the	 range	 of	 5.0‐1500.0	 ng/mL	 for	
azithromycin.	Standards	were	prepared	in	triplicates.	Similarly,	
quality	 control	 (QC)	 samples	 were	 also	 prepared	 as	 a	 bulk	
based	 on	 an	 independent	 weighing	 of	 standard	 drug,	 at	
concentrations	of	5.0	(Lower	Limit	of	Quantitation,	LLOQ),	10.0	
(low;	 Low	 Quality	 Control,	 QCL),	 400.0	 (middle;	 Medium	
Quality	 Control,	 QCM)	 and	 1200.0	 ng/mL	 (high;	 High	 Quality	
Control,	 QCH)	 as	 a	 single	 batch	 at	 each	 concentration.	 Each	
calibrations	 or	 QC	 solution	was	 prepared	 by	 spiking	 50	 μL	 of	
the	corresponding	stock	solution	into	450	μL	of	human	plasma,	
then	100	µL	of	Na2CO3	(30%,	w:v)	was	spiked.	Then	extraction	
with	6	mL	tert‐butyl	methyl	ether	was	done.	The	mixture	was	
vortexed	 for	 thirty	 seconds	 and	 centrifuged	 at	 4000	 rpm	 for	
five	 minutes.	 The	 organic	 layer	 was	 then	 separated	 and	
evaporated	 in	 Epindorff	 evaporator	 then	 the	 residue	 was	
reconstituted	with	250	µL	of	 IS	dissolved	in	mobile	phase	and	
injected.	
	
2.6.	Bio‐analytical	method	validation	
	
The	method	was	validated	in	accordance	with	international	
regulations	 [30].	The	parameters	determined	were	 selectivity,	
specificity,	 matrix	 effect,	 linearity,	 precision,	 accuracy,	
recovery,	stability	and	dilution	integrity.	
		
3.	Results	and	discussion	
	
3.1.	Method	development	
	
3.1.1.	MS‐MS	tuning	
	
Mass	parameters	were	tuned	in	both	positive	and	negative	
ionization	 modes	 for	 the	 drug.	 Good	 response	 was	 found	 in	
positive	 ionization	mode	 for	 both	 the	 drug	 and	 IS.	 The	 MRM	
state	file	parameters	were	optimized	to	maximize	the	response	
for	both	the	drug	and	IS	as	shown	in	Table	1.	The	product	 ion	
mass	spectrum	of	azithromycin	and	IS	are	presented	in	Figure	
3.	
	
	
	
Figure	3.	Mass	spectrum	of	pure	azithromycin	and	sildenafil	citrate	(IS).
	
	
3.1.2.	Chromatographic	separation		
	
Separation	 was	 attempted	 using	 various	 combinations	 of	
acetonitrile	 and	 buffers	 with	 varying	 contents	 of	 each	
component	 on	 different	 columns	 like	 C8	 and	 C18	 of	 different	
types	 like	Chromolith,	Hypersil,	Zorbax,	Kromasil	and	Intertsil	
etc.	Use	of	0.1	%	formic	acid	helped	in	achieving	good	response	
for	MS	detection	by	facilitating	ionization	of	the	ions.	A	mobile	
phase	 consisting	 of	 acetonitrile	 and	 0.1%	 formic	 acid	 (80:20,	
v:v)	 was	 found	 suitable	 for	 both	 the	 drug	 and	 IS.	 The	
chromatographic	 separation	 was	 performed	 at	 room	
temperature	on	Waters	C18	column	(50	mm	x	2.1	mm,	5	μm)	
which	gave	a	good	peak	shape	and	response	even	at	lower	limit	
of	 quantitation	 level.	 A	 flow‐rate	 of	 0.5	 mL/min	 produced	 a	
good	peak	shape	and	permitted	a	runtime	to	0.5	min.	
	
3.1.3.	Plasma	sample	extraction	
	
Different	 methods	 of	 sample	 extraction	 including	 protein	
precipitation	 with	 methanol	 or	 acetonitrile	 and	 liquid‐liquid	
extraction	 (LLE)	with	 different	 solvents	 commonly	 used	were	
attempted.	 Better	 recoveries	 were	 obtained	 with	 LLE	 using	
tert‐butyl	 methyl	 ether.	 Besides,	 LLE	 can	 be	 helpful	 in	
producing	 a	 spectroscopically	 clean	 sample	 and	 avoiding	 the	
introduction	of	nonvolatile	materials	onto	 the	column	and	MS	
system	 and	 also	 minimized	 the	 experimental	 cost.	 Clean	
samples	 are	 essential	 for	 minimizing	 ion	 suppression	 and	
matrix	 effect	 in	 LC‐MS/MS	 analyses.	 Tert‐butyl	 methyl	 ether	
was	 found	 to	 be	 optimal,	 which	 can	 produce	 a	 clean	
chromatogram	for	a	blank	plasma	sample	and	yield	the	highest	
recovery	for	the	drug	from	the	plasma.		
	
3.2.	Method	validation	
	
3.2.1.	Linearity	
	
Six	 calibration	 curves	 each	 consisting	 of	 a	 zero,	 non‐zero	
and	 calibration	 standards	 prepared	 in	 human	 plasma	 were	
chromatographed.	The	concentrations	of	calibration	standards	
cover	 the	 range	 (5	 ‐1500	ng/mL),	 the	 linearity	was	evaluated	
by	calculating	the	linear	regression	(correlation	coefficient,	r2),	
and	 by	 evaluating	 the	 back	 calculated	 concentrations	 of	 the	
calibration	standards.	The	lower	limit	of	quantification	(LLOQ)	
of	azithromycin	is	(5	ng/mL).	
Calibration	 curves	 are	 found	 to	 be	 consistently	 accurate	
and	 precise	 over	 the	 calibration	 range	 of	 5‐1500	 ng/mL.	 The	
mean	 correlation	 coefficient	 (r2)	 is	 equal	 to	 0.999.	 Back	
calculations	 were	 made	 from	 the	 calibration	 curves	 to	
determine	 drug	 concentrations	 of	 each	 calibration	 standard.	
Data	 are	 presented	 in	 Table	 2.	 A	 typical	 calibration	 curve	 is	
presented	in	Figure	4.	
	
3.2.2.	Selectivity		
	
The	selectivity	of	the	method	was	examined	by	analyzing	a	
blank	human	plasma	extract	and	a	blank	plasma	sample	spiked	
with	 IS	only	 (Figure	5).	As	shown	 in	 this	 figure,	no	significant	
interferences	were	observed	in	the	lots	of	human	plasma	used	
for	the	preparation	of	calibration	standards	and	quality	control	
samples.	
	
3.2.3.	LLOQ	
	
The	lowest	limit	of	reliable	quantification	for	the	drug	was	
set	at	the	concentration	of	the	LLOQ	which	is	the	lowest	quality	
control	 level	 with	 a	 coefficient	 of	 variation	 less	 than	 20	 %.	
LLOQ	is	5	ng/mL	with	a	signal	to	noise	ratio	of	6.1.	
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Table	2.	Back‐calculated	standards	from	each	calibration	curve.	
Calibration	no	 Nominal	concentrations	(ng/mL)
5	 25	 50 100 250 500 1000	 1500
1	 5.414	 24.873	 49.112 111.359 256.809 513.472 1004.263	 1558.137
2	 5.165	 25.455	 45.562 111.180 253.650 524.688 979.228	 1513.784
3	 5.240	 24.936	 42.811 110.972 246.615 515.740 1004.699	 1406.883
4	 6.054	 22.758	 42.811	 104.843	 240.341	 507.540	 981.047	 1513.023	
5	 5.868	 24.936	 42.811	 110.999	 246.615	 515.740	 1004.699	 1554.451	
6	 5.266	 22.000	 43.350 134.416 248.320 496.705 1004.699	 1538.047
N	 6	 6	 6 6 6 6 6	 6	
Mean	 5.501	 24.160	 44.410 113.961 248.725 512.314 996.439	 1514.054
SD	(±)	 0.370	 1.416	 2.539 10.332 5.813 9.427 12.642	 55.92411
CV	(%)	 6.723	 5.860	 5.717	 9.066	 2.337	 1.840	 1.269	 3.693667	
%	Nominal	 110.022 96.640	 88.819	 113.961	 99.490	 102.463	 99.644	 100.9369	
	
	
Table	3.	Intra‐day	accuracy	and	precision.	
Run	
number 
QCL	10	ng/mL	 QCM	400	ng/mL QCH	1200	ng/mL	
Conc.	found	(ng/mL)	 %	Nominal	conc.	 Conc.	found	(ng/mL) %	Nominal	conc. Conc.	found	(ng/mL)	 %	Nominal	conc.
1	 11.23	 112.3	 384	 96.00	 1202	 100.17	
2	 10.24	 102.36	 399	 99.75	 1125	 93.75	
3	 9.63	 96.32	 374	 93.50	 1136	 94.67	
4	 9.32	 93.21	 386 96.50 1189 99.08	
5	 9.75	 97.45	 401 100.25 1187 98.92	
6	 8.52	 85.21	 422 105.50 1120 93.33	
N	 6	 6	 6	 6	 6	 6	
Mean	 9.78	 97.81	 394.33	 98.58	 1159.83	 96.65	
SD	(±)	 0.91	 	 16.86	 36.70	
CV	(%)	 9.29	 	 4.28 3.16
	
	
	
	
Figure	4.	Standard	Calibration	curve	of	azithromycin	in	human	plasma.
	
	
	
Figure	5.	Mass	spectrum	of	blank	plasma	compared	to	that	containing	only	
IS.	
	
	
3.2.4.	Accuracy	and	precision	
	
3.2.4.1.	Intra‐day	accuracy	and	precision		
	
The	 intra‐day	 accuracy	 and	 precision	 evaluations	 were	
assessed	 by	 repeated	 analysis	 of	 human	 plasma	 samples	
containing	 different	 concentrations	 of	 Azithromycin	 on	
separate	 occasions,	 same	 day.	 A	 single	 run	 consisted	 of	 a	
calibration	curve	plus	6	runs	of	low	(QCL),	medium	(QCM)	and	
high	(QCH)	quality	control	samples,	the	intra‐day	coefficients	of	
variation	ranged	between	9.29,	4.28	and	3.16%.	The	intra‐day	
percentages	 of	 nominal	 concentration	 ranged	 between	 97.81,	
98.58	and	96.65%.	Results	are	presented	in	Table	3.	
3.2.4.2.	Inter‐day	accuracy	and	precision		
	
Inter‐day	 accuracy	 and	 precision	 evaluations	 were	
performed	 by	 analyzing	 three	 sets	 of	 QCL,	 QCM	 and	 QCH	
quality	control	samples	of	Azithromycin	in	human	plasma.	One	
set	was	extracted	and	analyzed	on	one	day	(Day	 I).	The	other	
two	sets	were	kept	frozen,	thawed,	extracted	and	analysed	on	a	
next	day	(Day	II)	for	the	second	set,	and	third	day	(Day	III)	for	
the	last	set.		
The	 inter‐day	 coefficients	 of	 variation	 ranged	 between	
14.50,	4.70	and	3.40%.		
The	inter‐day	percentages	of	nominal	concentration	ranged	
between	 90.90,	 97.30	 and	 98.90%.	 Results	 are	 presented	 in	
Table	4.	
	
3.2.5.	Extraction	efficiency	
	
Recovery	 of	 Azithromycin	 was	 evaluated	 by	 comparing	
mean	 analyte	 responses	 of	 two	 processed	 samples	 of	 low	
(QCL),	medium	(QCM)	and	high	(QCH)	quality	control	samples	
to	 mean	 analyte	 responses	 of	 the	 same	 concentrations	 with	
spiked	 samples	 in	 previously	 extracted	 blank	 plasma.	 Mean	
recovery	 values	 are	89.08,	97.02	 and	95.03%	at	 low,	medium	
and	 high	 quality	 control	 levels,	 respectively.	 Results	 are	
presented	in	Table	5.	
	
3.2.6.	Dilution	integrity	
	
Three	 replicates	 of	 the	 high	 quality	 control	 (QCH)	 were	
diluted	five	times	in	human	plasma	prior	to	sample	processing	
and	 analysis.	 The	 calculated	 concentrations,	 including	 the	
dilution	 factor,	 yielded	 coefficients	 of	 variation	 of	 4.48%	 for	
QCH.	 Percentages	 of	 nominal	 concentration	 are	 100.67%	
Results	are	presented	in	Table	6.	
	
3.2.7.	Stability	studies	
	
3.2.7.1	Post‐preparative	stability	at	10	°C	
	
Samples	 prepared	 at	 low	 (QCL),	medium	 (QCM)	 and	 high	
(QCH)	 quality	 control	 levels	were	 aliquoted	 and	 submitted	 to	
the	 sample	 processing	 procedure	 and	 kept	 at	 10	 °C	 (stability	
samples).		
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Table	4.	Inter‐day	accuracy	and	precision.	
Day	 Run	
number	
QCL	10	ng/mL	 QCM	400	ng/mL QCH	1200	ng/mL	
Conc.	found	
(ng/mL)	
%	Nominal	
conc.	
Conc.	found	
(ng/mL)	
%	Nominal	
conc.	
Conc.	found	
(ng/mL)	
%	Nominal	
conc.	
I	 1	 8.3	 83.2	 385.0 96.3 1203.0	 100.3
2	 8.4	 84.0	 386.0 96.5 1205.0	 100.4
3	 9.0	 90.0	 397.0 99.3 1220.0	 101.7
4	 10.0	 100.0	 375.0 93.8 1159.0	 96.6	
5	 10.8	 108.0	 402.0 100.5 1156.0	 96.3	
6	 11.3	 113.0	 406.0	 101.5	 1148.0	 95.7	
II	 1	 10.4	 103.6	 410.0	 102.5	 1149.0	 95.8	
2	 10.0	 100.0	 412.0	 103.0	 1157.0	 96.4	
3	 11.2	 112.0	 416.0 104.0 1169.0	 97.4	
4	 9.0	 90.0	 384.0 96.0 1158.0	 96.5	
5	 7.0	 70.0	 365.0 91.3 1126.0	 93.8	
6	 8.0	 80.0	 372.0 93.0 1136.0	 94.7	
III	 1	 9.9	 98.5	 379.0 94.8 1187.0	 98.9	
2	 8.5	 85.0	 377.0	 94.3	 1214.0	 101.2	
3	 7.6	 76.0	 388.0 97.0 1256.0	 104.7
4	 7.4	 74.0	 397.0 99.3 1236.0	 103.0
5	 7.9	 79.0	 346.0	 86.5	 1245.0	 103.8	
6	 8.9	 89.0	 406.0 101.5 1233.0	 102.8
N	 6.0	 6.0	 6.0	 6.0	 6.0	 6.0	
Mean	 9.1	 90.9	 389.1	 97.3	 1186.5	 98.9	
SD	(±)	 1.3	 	 18.4 40.7 	
CV	(%) 14.5	 	 4.7 3.4 	
	
	
Table	5.	Recovery	of	azithromycin.	
Extracted	sample	analyte	response Theoretical	true	spiked	in	matrix	analyte	response Analyte	samples	
Analyte	3Analyte	2	Analyte	1Analyte	3Analyte	2Analyte	1	
2854712 945876 16598 2854126 987541 18562 Sample	1 
2685471 952147 14856 2963514 965147 17451 Sample	2 
2596874 963214 19657 2745214 996321 21365 Sample	3 
3 3 3 3 3 3 N 
2712352.33 953745.667 17037.00 2854284.667 983003 19126.00 Mean 
131004.058 8778.85883 2430.42 109150.0865 16074.81421 2017.03 SD	(±) 
4.83 0.92 14.27 3.82 1.64 10.55 CV	(%) 
1200 400 10 1200 400 10 Concentration	(ng/mL) 
95.03 97.02 89.08  Mean	recovery	(%) 
	
	
Table	6.	Results	of	dilution	integrity.	
Analyte	samples	 Conc.	vound	(ng/mL) %	Nominal	concentration	
Sample	1	 1156.00 96.33
Sample	2	 1204.00 100.33
Sample	3	 1264.00 105.33
N	 3	 3
Mean	 1208.00 100.67
SD	(±)	 54.11	
CV	(%) 4.48	
	
	
	
Three	 replicates	 of	 those	 quality	 control	 samples	 were	
freshly	 processed	 with	 a	 calibration	 curve	 and	 analyzed	 in	 a	
single	 run	 to	 serve	 as	 time	 zero	 (comparison	 samples).	 After	
100	 hours,	 a	 calibration	 curve	 was	 freshly	 processed	 and	
analyzed	 with	 all	 stability	 samples	 in	 a	 single	 run.	
Concentrations	 were	 calculated	 to	 determine	 %	 change	 after	
100	hours	when	compared	to	time	zero.	Azithromycin	is	found	
to	be	stable	for	100	hours	at	10	°C	following	sample	processing	
with	 %	 changes	 of	 ‐9.71,	 ‐7.40	 and	 ‐2.68%.	 Results	 are	
presented	in	Table	7.	
	
3.2.7.2.	Short‐term	stability	of	azithromycin	in	matrix	at	
room	temperature	
	
Samples	were	prepared	at	 low	 (QCL),	medium	 (QCM)	and	
high	 (QCH)	 quality	 control	 levels.	 Three	 replicates	 of	 low,	
medium	 and	 high	 quality	 control	 samples	 were	 left	 at	 room	
(stability	 samples).	 Three	 replicates	 of	 those	 quality	 controls	
samples	were	 freshly	 processed	with	 a	 calibration	 curve	 and,	
analyzed	 in	 a	 single	 run	 to	 serve	 as	 time	 zero	 (comparison	
samples).	 After	 24	 hours,	 a	 calibration	 curve	 was	 freshly	
processed	 and	 analyzed	 with	 all	 stability	 samples	 in	 a	 single	
run.	 Concentrations	 were	 calculated	 to	 determine	 %	 change	
over	 the	 time	 when	 compared	 to	 time	 zero.	 Azithromycin	 is	
found	 to	 be	 stable	 in	 human	 plasma	 for	 24	 hours	 at	 room	
temperature	with	%	changes	of	‐9.34,	‐9.03	and	‐1.77%.	Results	
are	presented	in	Table	7.	
	
3.2.7.3.	Freeze	and	thaw	stability	at	‐20	°C	
	
Samples	were	prepared	at	 low	 (QCL),	medium	 (QCM)	and	
high	 (QCH)	 quality	 control	 levels,	 aliquoted	 and	 frozen	 at	 ‐20	
°C.	 Some	 of	 the	 aliquots	 of	 quality	 control	 samples	 were	
subjected	 to	 three	 freeze‐thaw	 cycles	 (stability	 samples).	 A	
calibration	 curve	 and	 quality	 control	 samples	 were	 freshly	
prepared	 and	processed	with	3	 replicates	 of	 stability	 samples	
and	analysed	in	a	single	run.	Azithromycin	is	found	to	be	stable	
in	human	plasma	after	three	freeze‐thaw	cycles	at,	‐20	°C	with	
coefficients	 of	 variation	 of	 7.78,	 1.71	 and	 1.48%	 and	nominal	
concentrations	of	103.66,	95.75	and	95.61%	for	QCL,	QCM	and	
QCH,	respectively.	Results	are	presented	in	Table	7.	
	
3.2.7.4.	Long‐term	stability	of	azithromycin	in	matrix	at	‐20	
°C	
	
Stability	 samples	were	 prepared	 in	 human	 plasma	 at	 low	
(QCL),	 medium	 (QCM)	 and	 high	 (QCH)	 quality	 control	 levels	
and	stored	at	‐20	°C	(stability	samples).		
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Table	7.	Summary	of	validation	results.	
Parameters	 Value	
Linearity	 r ≥	0.999
Calibration	curve	range	 	 5‐1500	ng/mL
Inter‐day	accuracy	 QC	%	nominal	conc.,	90.90,	97.30	and	98.90%		
Inter‐day	precision	 QC	coefficients	of	variation,	14.50,	4.70	and	3.40%	
Intra‐day	accuracy	 	 QC	%	nominal	conc.,	97.81,	98.58	and	96.65%	
Intra‐day	precision	 QC	coefficients	of	variation,	9.29,	4.28	and	3.16%	
Recovery	of	analyte	 QC	means,	89.08,	97.02	and	95.03%	
Lower	limit	of	quantification	 5	ng/mL	
Dilution	integrity	accuracy	 	 QC	%	nominal.	cone.,	100.67%
Dilution	integrity	precision	 	 QC	coefficient	of	variation,	4.48%
Post‐preparative	stability	at	10	°C	 Mean	%	change,	‐9.71,	‐7.40	and	‐2.68%	
Short‐term	stability	of	analyte	in	matrix	at	‐20	°C	 Mean	%	change	after	24	hours,	‐9.34,	‐9.03	and	‐1.77%	
Long‐term	stability	of	analyte	in	matrix	at	‐20	°C	 Mean	%	change	after	52	days,	‐11.12,	‐7.09	and	‐3.05%	
Freeze	and	thaw	stability	of	analyte	in	matrix	at	‐20	°C	 QC	%	nominal	conc.,	103.66,	95.75	and	95.61%	
	
	
A	calibration	curve	and	3	replicates	of	low	and	high	quality	
control	samples	(comparison	samples)	were	freshly	processed	
with	 three	 replicates	 of	 stability	 samples	 and	 analysed	 in	 a	
single	 run.	 Concentrations	 were	 calculated	 to	 determine	 %	
change	over	time.	Azithromycin	is	found	to	be	stable	in	human	
plasma	 for	 52	 days	 at	 ‐20	 °C	with	%	 changes	 of	 ‐11.12,	 ‐7.09	
and	‐3.05%.	Results	are	presented	in	Table	7.	
	
4.	Conclusion	
	
The	developed	LC‐MS/MS	assay	 for	 azithromycin	 is	 rapid,	
selective,	 and	 suitable	 for	 routine	 measurement	 of	 subject	
samples.	 This	 study	 reports	 a	 high	 throughput	 liquid‐liquid	
extraction	 method	 for	 extraction	 of	 azithromycin	 in	 human	
plasma	 using	 LC‐MS/MS.	 The	 developed	 method	 provided	 a	
short	run	time	of	about	0.5	minutes	that	can	afford	the	analysis	
of	more	than	400	plasma	samples	per	day.	The	present	method	
also	provided	excellent	specificity	and	linearity	with	an	LLOQ	of	
5	ng/mL	for	azithromycin.	
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